Track CTXR and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Citius Pharmaceuticals Inc
11 Commerce Drive, Cranford, NJ, United States, 07016
IPO
2017
Employees
23
Industry
Biotechnology
Sector
Healthcare
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20190+3
3
Q2 20190+2
2
Q3 20180+1
1
Q1 20180+1
1
Q3 20170+2
2
5-quarter cumulative
0 sells9 buys
Analyst Ratings
1 analysts covering
Hold100%recommend hold
Buy
0
Hold
1
Sell
0